85 related articles for article (PubMed ID: 17344916)
1. Expression of the JAK2 V617F mutation is not found in de novo AML and MDS but is detected in MDS-derived leukemia of megakaryoblastic nature.
Nishii K; Nanbu R; Lorenzo V F; Monma F; Kato K; Ryuu H; Katayama N
Leukemia; 2007 Jun; 21(6):1337-8. PubMed ID: 17344916
[No Abstract] [Full Text] [Related]
2. Hematologic and cytogenetic response to lenalidomide monotherapy in acute myeloid leukemia arising from JAK2(V617F) positive, del(5)(q13q33) myelodysplastic syndrome.
Mesa RA; Tefferi A; Li CY; Steensma DP
Leukemia; 2006 Nov; 20(11):2063-4. PubMed ID: 16990762
[No Abstract] [Full Text] [Related]
3. Pooled analysis of clinical and cytogenetic features in treatment-related and de novo adult acute myeloid leukemia and myelodysplastic syndromes based on a consecutive series of 761 patients analyzed 1976-1993 and on 5098 unselected cases reported in the literature 1974-2001.
Mauritzson N; Albin M; Rylander L; Billström R; Ahlgren T; Mikoczy Z; Björk J; Strömberg U; Nilsson PG; Mitelman F; Hagmar L; Johansson B
Leukemia; 2002 Dec; 16(12):2366-78. PubMed ID: 12454741
[TBL] [Abstract][Full Text] [Related]
4. The JAK2 V617F tyrosine kinase mutation in myelodysplastic syndromes (MDS) developing myelofibrosis indicates the myeloproliferative nature in a subset of MDS patients.
Ohyashiki K; Aota Y; Akahane D; Gotoh A; Miyazawa K; Kimura Y; Ohyashiki JH
Leukemia; 2005 Dec; 19(12):2359-60. PubMed ID: 16239910
[No Abstract] [Full Text] [Related]
5. Acute myeloid leukemia with MYC rearrangement and JAK2 V617F mutation.
Ohanian M; Bueso-Ramos C; Ok CY; Lin P; Patel K; Alattar ML; Khoury JD; Rozovski U; Estrov Z; Huh YO; Cortes J; Abruzzo LV
Cancer Genet; 2015 Nov; 208(11):571-4. PubMed ID: 26382622
[TBL] [Abstract][Full Text] [Related]
6. JAK2 V617F mutation in myeloid neoplasms with 3q21 and 3q26 abnormalities in Chinese patients.
Wong KF; Wong WS; Siu LL; Lau TC
Leuk Lymphoma; 2009 Aug; 50(8):1386-8. PubMed ID: 19562620
[No Abstract] [Full Text] [Related]
7. JAK2(V617F) mutation in myelodysplastic syndrome (MDS) with del(5q) arises in genetically discordant clones.
Sokol L; Caceres G; Rocha K; Stockero KJ; Dewald DW; List AF
Leuk Res; 2010 Jun; 34(6):821-3. PubMed ID: 19819015
[TBL] [Abstract][Full Text] [Related]
8. Activating mutations of JAK2V617F are uncommon in t-MDS and t-AML and are only observed in atypic cases.
Desta F; Christiansen DH; Andersen MK; Pedersen-Bjergaard J
Leukemia; 2006 Mar; 20(3):547-8. PubMed ID: 16424876
[No Abstract] [Full Text] [Related]
9. Molecular heterogeneity in AML/MDS patients with 3q21q26 rearrangements.
Lahortiga I; Vázquez I; Agirre X; Larrayoz MJ; Vizmanos JL; Gozzetti A; Calasanz MJ; Odero MD
Genes Chromosomes Cancer; 2004 Jul; 40(3):179-89. PubMed ID: 15138998
[TBL] [Abstract][Full Text] [Related]
10. Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities.
Pedersen-Bjergaard J; Christiansen DH; Andersen MK; Skovby F
Leukemia; 2002 Nov; 16(11):2177-84. PubMed ID: 12399959
[TBL] [Abstract][Full Text] [Related]
11. Rare occurrence of mutations of the FLR exon of the neurofibromatosis 1 (NF1) gene in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML).
Preudhomme C; Vachee A; Quesnel B; Wattel E; Cosson A; Fenaux P
Leukemia; 1993 Jul; 7(7):1071. PubMed ID: 8321023
[No Abstract] [Full Text] [Related]
12. Essential thrombocythemia during treatment of acute myeloid leukemia with JAK2 V617F mutation: A case report of a CARE-compliant article.
Ding W; Li D; Zhuang C; Wei P; Mou W; Zhang L; Liang H; Liu Y
Medicine (Baltimore); 2018 Jul; 97(27):e11331. PubMed ID: 29979407
[TBL] [Abstract][Full Text] [Related]
13. [Classification of myeloid leukemias].
Kuriyama K
Nihon Rinsho; 2009 Oct; 67(10):1853-62. PubMed ID: 19860179
[TBL] [Abstract][Full Text] [Related]
14. Alternative genetic pathways and cooperating genetic abnormalities in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia.
Pedersen-Bjergaard J; Christiansen DH; Desta F; Andersen MK
Leukemia; 2006 Nov; 20(11):1943-9. PubMed ID: 16990778
[TBL] [Abstract][Full Text] [Related]
15. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases.
Orazi A
Pathobiology; 2007; 74(2):97-114. PubMed ID: 17587881
[TBL] [Abstract][Full Text] [Related]
16. Myeloid sarcoma with megakaryoblastic differentiation mimicking a sellar tumor.
Novello M; Coli A; Della Pepa GM; Martini M; Doglietto F; De Stefano V; Bellesi S; Pescarmona E; Lauriola L
Neuropathology; 2014 Apr; 34(2):179-84. PubMed ID: 24118374
[TBL] [Abstract][Full Text] [Related]
17. Novel immunophenotypic and morphologic presentation in acute myeloid leukemia (AML) with JAK2 V617F mutation.
Swaminathan S; Madkaikar M; Ghosh K; Vundinti BR; Kerketta L; Gupta M
Eur J Haematol; 2010 Feb; 84(2):180-2. PubMed ID: 19824900
[No Abstract] [Full Text] [Related]
18. Therapy-related acute myeloid leukemia/myelodysplasia with balanced 21q22 translocations.
Arber DA; Slovak ML; Popplewell L; Bedell V; Ikle D; Rowley JD;
Am J Clin Pathol; 2002 Feb; 117(2):306-13. PubMed ID: 11863228
[TBL] [Abstract][Full Text] [Related]
19. Rearrangement and expression of the p53 gene in myelodysplastic syndrome and acute myeloid leukemia.
Fenaux P; Collyn d'Hooghe M; Jonveaux P; Lai JL; Bauters F; Loucheux MH; Kerckaert JP
Nouv Rev Fr Hematol (1978); 1990; 32(5):341-4. PubMed ID: 2099408
[TBL] [Abstract][Full Text] [Related]
20. Myelodysplastic syndromes and acute myeloid leukemia with 17p deletion. An entity characterized by specific dysgranulopoïesis and a high incidence of P53 mutations.
Lai JL; Preudhomme C; Zandecki M; Flactif M; Vanrumbeke M; Lepelley P; Wattel E; Fenaux P
Leukemia; 1995 Mar; 9(3):370-81. PubMed ID: 7885035
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
